BioPharm Asia, Inc. (OTCBB: BFAR; the ?Company?), a producer, distributor and retailer of medicinal and herbal products in China, today announced that Mr. Shengqun Li has been appointed as its Chief Executive Officer and Mr. Jianxiong Liu has been appointed as its Chief Financial Officer. Mr. Li and Mr. Liu replace Mr. Qin who resigned his positions as the Company's acting Chief Executive Officer and Chief Financial Officer on July 26, 2010.

Mr. Shengqun Li, age 45, was Vice President of Mergers and Acquisitions of Topchoice Medical Investment Corporation, which is listed on the Shanghai Stock Exchange (?600763?) from September 2007 to May, 2010. Topchoice Medical Investment Corporation manages a chain of dental hospitals. From October 2000 to June, 2007, he was Vice President of Mergers and Acquisition of Medika Industrial Co., Ltd. which manages several woman's health hospitals. Mr. Li graduated from Huazhong University of Science and Technology.

Before joining BioPharm Asia as its CFO, Mr. Jianxiong Liu, age 39, was the Financial Controller of the Chinese operations of AnyDATA Corporation, a US corporation headquartered in California which designs and manufactures telecommunication devices. He has over 15 years of broad financial experience. Mr. Liu has a MBA degree from University of Glamorgan (United Kingdom). He is a Chartered Certified Accountant and a holder of a China Registered Tax Certificate.

Under this new management team, BioPharm Asia expects to achieve further growth in its retail and distribution segments, while expanding into the Medicare industry through its newly acquired Zhihe Ruikang Hospital Management Ltd. entity. ?BioPharm Asia has a number of great opportunities,? said Mr. Li, ?I am honored and very excited to lead BioPharm Asia to take actions to increase its distribution network and expand the number of its retail stores. I also expect that we will soon begin to realize our strategy to enable the Company to expand into health care provider services. We anticipate that our management and systems resources will enable hospitals to transition from traditional, low profit operations to modern, system-based health care providers with attractive margins.?

Mr. Li also commented, ?I am very much looking forward to working closely with Mr. Liu, who has considerable experience in finance, to enable BioPharm Asia to reach its potential in China's rapidly expanding medical support field.?

About BioPharm Asia, Inc.

BioPharm Asia, Inc. is engaged in the retail sale of medicinal and herbal products in China, complemented by vertically integrated supporting functions that include the cultivation of Chinese herbal medicines, pharmaceutical production and wholesale medicine distribution. Following several successful acquisitions, the Company is completing the integration of its distribution channels and expanding its trading business (conducted through its retail stores as well as its distribution activities) to include pharmaceutical manufacturing and the cultivation and sale of medicinal raw materials. For more information, please visit http://www.biopharmasiainc.com.

Forward-looking statement: Except for certain historical information contained herein, the matters discussed in this news release contain forward-looking statements, including, but not limited to, statements relating to future expansion plans and growth in sales. These forward-looking statements involve a number of risks and uncertainties. Actual results may differ materially from those implied herein due to a number of factors, including, but not limited to, uncertainties in product demand, risks related to doing business in China, the impact of competitive products and pricing, changing economic conditions around the world, release and sales of new products and other risk factors discussed in the company's most recent annual report and other filings with the U. S. Securities and Exchange Commission.

BioPharm Asia Inc.
Jianxiong Liu, 011-86-435-5211804
Jianxiong_Liu@biopharmasiaco.com